Recent developments highlight ALR Technologies' progress in manufacturing and commercializing the GluCurve Pet CGM, including a definitive manufacturing agreement, plans for a product relaunch in January 2026, and expansion into the Canadian market. The company also announced a patent grant for its predictive A1C algorithm and partnerships to support distribution.

• ALR Technologies announced plans to relaunch the GluCurve Pet CGM in January 2026 [N1].
• The company completed a definitive manufacturing agreement for the GluCurve Pet CGM in June 2025 [N2].
• ALR Technologies received a patent grant for its Predictive A1C algorithm and reported successful results from a Singapore General Hospital-led study in September 2023 [N3].
• The company announced Canadian launch plans for the GluCurve Pet CGM in August 2023 [N4].
• ALR Technologies announced the second generation GluCurve Pet CGM for diabetic cats and dogs in June 2023 [N5].
• A co-branded distribution partnership with Covetrus for the GluCurve Pet CGM was announced in December 2022 [N8].
• The company provided sales guidance for Q4 2022 and Q1 2023 and completed the GluCurve Pet CGM manufacturing agreement in December 2022 [N7].
• Covetrus showcased innovation and technology at VMX 2023, supporting the partnership with ALR Technologies [N6].

The company has developed a unique diabetes management platform with FDA clearance and a patent-pending predictive algorithm, which could differentiate its offerings in both human and veterinary markets. The upcoming relaunch of the next generation GluCurve Pet CGM and established manufacturing and distribution agreements indicate progress toward commercialization. Strategic partnerships, such as with Covetrus, may enhance market access and adoption in the veterinary segment.

ALR Technologies faces significant financial risks including a severe working capital deficiency, substantial debt obligations, and ongoing net losses. The company has generated minimal revenue to date and depends heavily on related party financing and lines of credit. Legal judgments and creditor actions related to overdue promissory notes add to financial uncertainty. The ability to sustain operations and achieve profitable commercialization remains uncertain.

ALR Technologies' moat lies in its FDA-cleared integrated diabetes management system and proprietary predictive A1C algorithm, which provide a comprehensive approach to diabetes care. The adaptation of this technology for veterinary use with the GluCurve Pet CGM, combined with partnerships such as the co-branded distribution with Covetrus, creates a niche position in the diabetic pet care market. However, the company's financial constraints and limited commercial traction currently limit the strength of this moat.

• Financial Risk: The company has a severe working capital deficiency, significant current liabilities exceeding current assets, and relies on related party financing and lines of credit to fund operations. There is substantial doubt about its ability to repay current liabilities, which could lead to business failure [S2].
• Operational Risk: ALR Technologies has yet to generate meaningful revenue and depends on successful commercialization of the GluCurve Pet CGM product. Delays or failures in product launch or market adoption could impact viability [N1][S2].
• Legal and Credit Risk: The company faces multiple judgments related to overdue promissory notes and accrued interest, with some creditors having initiated legal action. This adds uncertainty to financial stability [S2].
• Market and Competitive Risk: The diabetes care and veterinary device markets are competitive and evolving. The company's ability to maintain FDA clearance, protect intellectual property, and differentiate its products is critical [S2].

• ALR Technologies SG Ltd. is a data management company focused on diabetes care solutions, including a FDA-cleared diabetes management system integrating blood glucose meters and continuous glucose monitoring (CGM) devices [S2].
• The company has developed a Diabetes Solution product for human health and a modified version called GluCurve Pet CGM for animal health, targeting diabetic cats and dogs [S2].
• GluCurve Pet CGM assists veterinarians in optimizing insulin treatment for companion animals by monitoring glucose levels continuously [S2].
• ALR Technologies has completed a definitive manufacturing agreement for the GluCurve Pet CGM and plans to relaunch the next generation of this product in January 2026 [N1][N2].
• The company announced Canadian launch plans for the GluCurve Pet CGM and has a co-branded distribution partnership with Covetrus, a veterinary technology company [N4][N8].
• ALR Technologies holds a patent for a Predictive A1C algorithm and reported successful clinical study results led by Singapore General Hospital [N3].
• The company reported minimal revenue recognized in 2022 and no revenue in 2025 to date, with plans to generate revenue from the next generation GluCurve Pet CGM in early 2026 [S2][N1].
• Financial snapshot as of December 31, 2025, shows revenue of $25,536 USD, net loss of $22,057,792 USD, and diluted EPS of -$0.04 USD per share [S1].
• Current liabilities as of December 31, 2023, were $32,071,353 USD, with no disclosed cash or short-term investments, resulting in a cash ratio of 0 [S1].
• The company has a severe working capital deficiency and relies on lines of credit and related party financing to fund operations and product development [S2].
• ALR Technologies has significant debt obligations including promissory notes, loans payable, and accrued interest, some of which are in default or due on demand [S2].
• The CEO and Chairman, Sidney Chan, holds warrants exercisable at $0.002 per share, extended to December 31, 2026 [S2].
• The company incurred substantial operating losses and interest expenses in the first half of 2025, with net loss of approximately $10.77 million USD [S2].
• Share-based compensation is a significant non-cash expense impacting operating costs [S2].
• The company operates primarily in Singapore and the United States, with one operating segment focused on diabetes hardware and software development [S2].